(Source: Conatus Pharmaceuticals Inc) SAN DIEGO, Nov. 4, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2015, and provided updates on its clinical development programs. Financial Results The net loss for the third quarter of 2015 was $6.1 million compared with $6.4 million for the third quarter of 2014. The net loss for the first nine months of 2015 was $18.1 million compared with $17.0 million for the first nine months of 2014. Research and development expenses were $4.1...
↧